Healthcare & Life Sciences
Pharma, biotech, devices, tools and managed care.
Zoetis Inc (ZTS)
HOLD. 12-month probability-weighted target $75 (-3% vs spot). P/E Multiple explains 79% of Monte Carlo outcome variance.
Zimmer Biomet Holdings Inc (ZBH)
HOLD. 12-month probability-weighted target $90 (-11% vs spot). P/E Multiple explains 63% of Monte Carlo outcome variance.
Dentsply Sirona Inc (XRAY)
BUY. 12-month probability-weighted target $14 (+24% vs spot). Gross Margin explains 67% of Monte Carlo outcome variance.
West Pharmaceutical Services Inc (WST)
HOLD. 12-month probability-weighted target $343 (-3% vs spot). P/E Multiple explains 62% of Monte Carlo outcome variance.
Waters Corporation (WAT)
SELL. 12-month probability-weighted target $365 (-11% vs spot). P/E Multiple explains 84% of Monte Carlo outcome variance.
Viatris Inc (VTRS)
BUY. 12-month probability-weighted target $20 (+21% vs spot). P/E Multiple explains 65% of Monte Carlo outcome variance.
Vertex Pharmaceuticals Inc (VRTX)
SELL. 12-month probability-weighted target $466 (-15% vs spot). P/E Multiple explains 84% of Monte Carlo outcome variance.
United Therapeutics Corporation (UTHR)
HOLD. 12-month probability-weighted target $516 (+1% vs spot). P/E Multiple explains 86% of Monte Carlo outcome variance.
UnitedHealth Group Incorporated (UNH)
HOLD. 12-month probability-weighted target $400 (+0% vs spot). Gross Margin explains 67% of Monte Carlo outcome variance.
Universal Health Services Inc (UHS)
SELL. 12-month probability-weighted target $140 (-20% vs spot). Gross Margin explains 64% of Monte Carlo outcome variance.
Thermo Fisher Scientific Inc (TMO)
SELL. 12-month probability-weighted target $512 (-19% vs spot). P/E Multiple explains 69% of Monte Carlo outcome variance.
Tenet Healthcare Corporation (THC)
SELL. 12-month probability-weighted target $202 (-28% vs spot). Gross Margin explains 65% of Monte Carlo outcome variance.
Stryker Corporation (SYK)
HOLD. 12-month probability-weighted target $314 (-4% vs spot). P/E Multiple explains 69% of Monte Carlo outcome variance.
STERIS plc (STE)
SELL. 12-month probability-weighted target $210 (-12% vs spot). P/E Multiple explains 60% of Monte Carlo outcome variance.
Sotera Health Co (SHC)
HOLD. 12-month probability-weighted target $17 (-9% vs spot). P/E Multiple explains 73% of Monte Carlo outcome variance.
Revvity Inc. (RVTY)
SELL. 12-month probability-weighted target $108 (-12% vs spot). P/E Multiple explains 65% of Monte Carlo outcome variance.
ResMed Inc (RMD)
SELL. 12-month probability-weighted target $201 (-13% vs spot). P/E Multiple explains 78% of Monte Carlo outcome variance.
Repligen Corporation (RGEN)
SELL. 12-month probability-weighted target $126 (-31% vs spot). P/E Multiple explains 76% of Monte Carlo outcome variance.
Regeneron Pharmaceuticals Inc (REGN)
SELL. 12-month probability-weighted target $617 (-25% vs spot). P/E Multiple explains 80% of Monte Carlo outcome variance.
Insulet Corporation (PODD)
HOLD. 12-month probability-weighted target $151 (+4% vs spot). P/E Multiple explains 52% of Monte Carlo outcome variance.
Pfizer Inc (PFE)
SELL. 12-month probability-weighted target $23 (-17% vs spot). P/E Multiple explains 75% of Monte Carlo outcome variance.
Option Care Health Inc (OPCH)
SELL. 12-month probability-weighted target $21 (-10% vs spot). Gross Margin explains 64% of Monte Carlo outcome variance.
Envista Holdings Corp (NVST)
HOLD. 12-month probability-weighted target $26 (-4% vs spot). Gross Margin explains 67% of Monte Carlo outcome variance.
Neurocrine Biosciences Inc (NBIX)
HOLD. 12-month probability-weighted target $172 (+12% vs spot). P/E Multiple explains 71% of Monte Carlo outcome variance.
Mettler-Toledo International Inc (MTD)
SELL. 12-month probability-weighted target $1246 (-11% vs spot). P/E Multiple explains 72% of Monte Carlo outcome variance.
Merck & Company Inc (MRK)
SELL. 12-month probability-weighted target $122 (-19% vs spot). P/E Multiple explains 64% of Monte Carlo outcome variance.
Medpace Holdings Inc (MEDP)
SELL. 12-month probability-weighted target $529 (-15% vs spot). P/E Multiple explains 62% of Monte Carlo outcome variance.
Medtronic PLC (MDT)
HOLD. 12-month probability-weighted target $86 (-7% vs spot). P/E Multiple explains 66% of Monte Carlo outcome variance.
McKesson Corporation (MCK)
HOLD. 12-month probability-weighted target $781 (-11% vs spot). Gross Margin explains 81% of Monte Carlo outcome variance.
Lantheus Holdings Inc (LNTH)
HOLD. 12-month probability-weighted target $104 (+3% vs spot). P/E Multiple explains 70% of Monte Carlo outcome variance.
Eli Lilly and Company (LLY)
SELL. 12-month probability-weighted target $1100 (-12% vs spot). P/E Multiple explains 86% of Monte Carlo outcome variance.
LivaNova PLC (LIVN)
HOLD. 12-month probability-weighted target $79 (+1% vs spot). P/E Multiple explains 55% of Monte Carlo outcome variance.
Laboratory Corporation of America Holdings (LH)
SELL. 12-month probability-weighted target $281 (-17% vs spot). Gross Margin explains 58% of Monte Carlo outcome variance.
Johnson & Johnson (JNJ)
SELL. 12-month probability-weighted target $240 (-12% vs spot). P/E Multiple explains 78% of Monte Carlo outcome variance.
Jazz Pharmaceuticals PLC (JAZZ)
HOLD. 12-month probability-weighted target $252 (-1% vs spot). P/E Multiple explains 89% of Monte Carlo outcome variance.
Intuitive Surgical Inc (ISRG)
HOLD. 12-month probability-weighted target $404 (+8% vs spot). P/E Multiple explains 81% of Monte Carlo outcome variance.
IQVIA Holdings Inc (IQV)
SELL. 12-month probability-weighted target $189 (-27% vs spot). Gross Margin explains 48% of Monte Carlo outcome variance.
Incyte Corporation (INCY)
SELL. 12-month probability-weighted target $107 (-16% vs spot). P/E Multiple explains 78% of Monte Carlo outcome variance.
Illumina Inc (ILMN)
SELL. 12-month probability-weighted target $187 (-16% vs spot). P/E Multiple explains 63% of Monte Carlo outcome variance.
IDEXX Laboratories Inc (IDXX)
HOLD. 12-month probability-weighted target $542 (-3% vs spot). P/E Multiple explains 75% of Monte Carlo outcome variance.
Humana Inc (HUM)
SELL. 12-month probability-weighted target $223 (-42% vs spot). Gross Margin explains 86% of Monte Carlo outcome variance.
Henry Schein Inc (HSIC)
HOLD. 12-month probability-weighted target $84 (-6% vs spot). Gross Margin explains 71% of Monte Carlo outcome variance.
HealthEquity Inc (HQY)
HOLD. 12-month probability-weighted target $99 (-6% vs spot). P/E Multiple explains 78% of Monte Carlo outcome variance.
HCA Healthcare, Inc. (HCA)
HOLD. 12-month probability-weighted target $398 (-7% vs spot). Gross Margin explains 63% of Monte Carlo outcome variance.
Halozyme Therapeutics Inc (HALO)
SELL. 12-month probability-weighted target $79 (-28% vs spot). P/E Multiple explains 88% of Monte Carlo outcome variance.
Haemonetics Corporation (HAE)
SELL. 12-month probability-weighted target $79 (-27% vs spot). P/E Multiple explains 59% of Monte Carlo outcome variance.
Globus Medical (GMED)
SELL. 12-month probability-weighted target $76 (-9% vs spot). P/E Multiple explains 64% of Monte Carlo outcome variance.
Gilead Sciences Inc (GILD)
SELL. 12-month probability-weighted target $122 (-17% vs spot). P/E Multiple explains 81% of Monte Carlo outcome variance.
GE HealthCare Technologies Inc. (GEHC)
SELL. 12-month probability-weighted target $63 (-15% vs spot). Gross Margin explains 62% of Monte Carlo outcome variance.
Exelixis Inc (EXEL)
HOLD. 12-month probability-weighted target $57 (+4% vs spot). P/E Multiple explains 92% of Monte Carlo outcome variance.
Edwards Lifesciences Corp (EW)
HOLD. 12-month probability-weighted target $88 (-3% vs spot). P/E Multiple explains 75% of Monte Carlo outcome variance.
The Ensign Group Inc (ENSG)
SELL. 12-month probability-weighted target $121 (-32% vs spot). Gross Margin explains 65% of Monte Carlo outcome variance.
Elevance Health Inc (ELV)
HOLD. 12-month probability-weighted target $377 (-6% vs spot). Gross Margin explains 68% of Monte Carlo outcome variance.
Elanco Animal Health (ELAN)
HOLD. 12-month probability-weighted target $25 (+1% vs spot). Gross Margin explains 55% of Monte Carlo outcome variance.
Encompass Health Corp (EHC)
SELL. 12-month probability-weighted target $96 (-21% vs spot). Gross Margin explains 58% of Monte Carlo outcome variance.
DexCom Inc (DXCM)
SELL. 12-month probability-weighted target $65 (-28% vs spot). P/E Multiple explains 64% of Monte Carlo outcome variance.
DaVita HealthCare Partners Inc (DVA)
BUY. 12-month probability-weighted target $215 (+22% vs spot). Gross Margin explains 65% of Monte Carlo outcome variance.
Danaher Corporation (DHR)
HOLD. 12-month probability-weighted target $194 (-10% vs spot). P/E Multiple explains 73% of Monte Carlo outcome variance.
Quest Diagnostics Incorporated (DGX)
SELL. 12-month probability-weighted target $204 (-16% vs spot). Gross Margin explains 57% of Monte Carlo outcome variance.
CVS Health Corp (CVS)
HOLD. 12-month probability-weighted target $103 (+9% vs spot). Gross Margin explains 68% of Monte Carlo outcome variance.
Charles River Laboratories (CRL)
SELL. 12-month probability-weighted target $209 (-30% vs spot). P/E Multiple explains 49% of Monte Carlo outcome variance.
Cencora Inc. (COR)
SELL. 12-month probability-weighted target $283 (-13% vs spot). Gross Margin explains 82% of Monte Carlo outcome variance.
The Cooper Companies, Inc (COO)
HOLD. 12-month probability-weighted target $70 (-8% vs spot). P/E Multiple explains 67% of Monte Carlo outcome variance.
Centene Corp (CNC)
HOLD. 12-month probability-weighted target $64 (-2% vs spot). Gross Margin explains 83% of Monte Carlo outcome variance.
Cigna Corp (CI)
HOLD. 12-month probability-weighted target $273 (-2% vs spot). Gross Margin explains 68% of Monte Carlo outcome variance.
Chemed Corp (CHE)
HOLD. 12-month probability-weighted target $516 (-5% vs spot). Gross Margin explains 49% of Monte Carlo outcome variance.
Cardinal Health Inc (CAH)
HOLD. 12-month probability-weighted target $235 (+1% vs spot). Gross Margin explains 84% of Monte Carlo outcome variance.
Boston Scientific Corp (BSX)
SELL. 12-month probability-weighted target $44 (-11% vs spot). P/E Multiple explains 71% of Monte Carlo outcome variance.
Bruker Corporation (BRKR)
HOLD. 12-month probability-weighted target $55 (-3% vs spot). P/E Multiple explains 57% of Monte Carlo outcome variance.
Bristol-Myers Squibb Company (BMY)
SELL. 12-month probability-weighted target $57 (-16% vs spot). P/E Multiple explains 76% of Monte Carlo outcome variance.
Biomarin Pharmaceutical Inc (BMRN)
SELL. 12-month probability-weighted target $59 (-9% vs spot). P/E Multiple explains 78% of Monte Carlo outcome variance.
Bio-Rad Laboratories Inc (BIO)
SELL. 12-month probability-weighted target $299 (-22% vs spot). Gross Margin explains 64% of Monte Carlo outcome variance.
Biogen Inc (BIIB)
SELL. 12-month probability-weighted target $194 (-11% vs spot). P/E Multiple explains 68% of Monte Carlo outcome variance.
Becton Dickinson and Company (BDX)
SELL. 12-month probability-weighted target $147 (-23% vs spot). P/E Multiple explains 56% of Monte Carlo outcome variance.
Baxter International Inc (BAX)
SELL. 12-month probability-weighted target $20 (-23% vs spot). Gross Margin explains 67% of Monte Carlo outcome variance.
Avantor Inc (AVTR)
SELL. 12-month probability-weighted target $11 (-25% vs spot). Gross Margin explains 64% of Monte Carlo outcome variance.
Amgen Inc (AMGN)
SELL. 12-month probability-weighted target $355 (-20% vs spot). P/E Multiple explains 80% of Monte Carlo outcome variance.
Align Technology Inc (ALGN)
HOLD. 12-month probability-weighted target $169 (+6% vs spot). P/E Multiple explains 64% of Monte Carlo outcome variance.
Abbott Laboratories (ABT)
SELL. 12-month probability-weighted target $93 (-20% vs spot). P/E Multiple explains 66% of Monte Carlo outcome variance.
AbbVie Inc (ABBV)
HOLD. 12-month probability-weighted target $236 (-11% vs spot). P/E Multiple explains 84% of Monte Carlo outcome variance.
Agilent Technologies Inc (A)
SELL. 12-month probability-weighted target $133 (-13% vs spot). P/E Multiple explains 72% of Monte Carlo outcome variance.
Bio-Techne Corp (TECH)
At roughly $71, on the engine's base earnings near $2.01 the stock trades close to a mid-thirties forward multiple. That price says the market expects biopharma R&D and bioprocessing demand to normalise to…